Navigation Links
BIO Visitors Bring Viral Preparedness to Atlanta
Date:5/20/2009

North Carolina giveaways show state's growing germ-fighting focus

ATLANTA, May 20 /PRNewswire-USNewswire/ -- Representatives of the North Carolina contingent to this week's Biotechnology Industry Organization (BIO) conference in Atlanta are pressing a point as they press the flesh with thousands of conference participants and residents.

The North Carolina Biotechnology Center is distributing hundreds of containers of hand sanitizers -- two brands, both from North Carolina-based companies. One, Purell, is alcohol-based. The other, Remi-D, is a new FDA-approved product that kills germs without alcohol.

The idea is to help visitors to the conference feel more relaxed about shaking hands while shaking the bushes for business connections on the crowded trade-show floor during this belated flu season. The giveaway, which includes some informal distribution to pedestrians in downtown Atlanta during the week, also high-fives North Carolina's growing reputation as the epicenter of infectious-disease weaponry.

For example, the Old North State is home not only to the companies that make Purell and Remi-D, but also to the North American headquarters of global pharmaceutical titan GlaxoSmithKline.

GSK is one of only two manufacturers in the world that make antiviral flu treatments. The U.S. Centers for Disease Control and Prevention, the World Health Organization and other health groups note that GSK's Relenza is effective against the 2009 strain of A (H1N1) flu virus, often called swine flu.

Relenza is made at the company's plant in Zebulon, about 25 miles east of its RTP headquarters.

Meanwhile, a history-making, 430,000-square-foot flu-vaccine plant is being built by Swiss drug maker Novartis AG in Holly Springs, about 20 miles southwest of Raleigh.

It's the largest biomanufacturing project under construction in the United States. The U.S. Department of Health and Human Services has promised $487 million for construction to strengthen the country's capacity to supply vaccines against seasonal flu or global pandemics.

About 45 miles north of the Novartis factory, in Durham, Merck recently dedicated its new $750 million vaccine-manufacturing plant. Merck already operates a biomanufacturing facility in Wilson.

The state's biomanufacturing capabilities extend beyond vaccines and antivirals to include biologics, pharmaceuticals and diagnostics. The complete line-up includes products from more than 50 companies, including Biogen Idec, Novozymes, Pfizer, Talecris, Wyeth and the aforementioned GSK, Novartis and Merck.

"Skilled labor is the engine that drives successful biomanufacturing operations," said Bill Bullock, the Biotechnology Center's vice president of bioscience industrial development. "North Carolina has spent nearly $100 million building and refining that engine. Add to that the fact that we're already home to some of the world's best universities and the world's largest concentration of contract research organizations, and what you have is an incredible environment for bioscience research, development and manufacturing.

"Also, of the top biotech states, North Carolina's cost of doing business is by far the lowest."

North Carolina has invested $1.2 billion in steady bioscience growth during the past decade alone, said E. Norris Tolson, president and CEO of the North Carolina Biotechnology Center.

"Some states aren't so interested in manufacturing. But at times like these, it becomes clear why these science-driven factories are so crucial. It reinforces our deep and longstanding commitment to biotechnology. There's no better place in the world to make medicines.

"Biomanufacturers have found a comfort zone in North Carolina. We're glad of it. And increasingly, the world is becoming glad of it too."

Charlotte-based LifeLogic Products produces Remi-D. Purell is made by QualPak, a privately owned company in Laurinburg, N.C.

The 2009 Biotechnology Industry Organization (BIO) International Convention is expected to draw between 12,000-15,000 visitors to Atlanta this week. More than 5,000 will come from outside the U.S.

The Biotechnology Center is a private, non-profit corporation supported by the N.C. General Assembly. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business, education and strategic policy statewide.

Visit the Biotechnology Center's Web site at www.ncbiotech.org


'/>"/>
SOURCE North Carolina Biotechnology Center
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009
2. Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for Best and Brightest Forum on Medical Innovation
3. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
4. Seminar Will Bring ALS Researchers to Patient Groups
5. Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m
6. Smallest ever quantum dots bring real world applications closer
7. U of T chemistry discovery brings organic solar cells a step closer
8. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
9. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
10. Nonprofit Puts the Power to Cure Neurological Disease in the Hands of the Masses: Texting Technology Brings Awareness & Supports Research
11. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):